CCEL

BEARISH

$3.67 Live

Cryo-Cell International, Inc. · AMEX

$2.72 52W Range $6.35

CCEL Cryo-Cell International, Inc. - Fundamental Analysis

BEARISH

Console Chart News

CCEL Stock | Fundamental Analysis & Investment Insights

AMEX • Healthcare • Medical Care Facilities

Current Price Live

$3.67

52W High

$6.35

52W Low

$2.72

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 25, 2026

Market cap

$29.56M

P/E

N/A

ROE

N/A

Profit margin

-8.5%

Debt/Equity

N/A

Dividend yield

16.35%

AI Analysis

AI-powered fundamental assessment

Confidence

95%

CCEL exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a negative Price/Book ratio of -1.61, suggesting negative shareholder equity. The company's dividend is fundamentally unsustainable with a payout ratio of 3962.91%, indicating that dividends are being paid out of capital or debt rather than earnings. While gross margins remain strong, the combination of declining YoY revenue (-3.60%) and crashing earnings growth (-80.50%) creates a precarious outlook. Liquidity is a critical concern with a current ratio of 0.62, placing the firm at significant short-term financial risk.

Key Strengths

Strong gross margins at 63.53%

Positive operating margin of 9.96%

Low Price/Sales ratio of 0.95

Recent history of beating earnings estimates (3 of last 4 quarters)

Short-term positive price momentum over the last 30 days (+23.6%)

Key Risks

Negative equity as indicated by Price/Book ratio of -1.61

Severe liquidity risk with a current ratio of 0.62 and quick ratio of 0.55

Unsustainable dividend payout ratio (3962.91%)

Significant decline in YoY earnings growth (-80.50%)

Micro-cap volatility and lack of analyst coverage

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High Risk / Avoid

Key drivers: Negative Book Value, Liquidity Crisis, Unsustainable Dividend, Weak Piotroski Score

Confidence

90%

Value

20/100

Valuation is distorted by negative equity and minimal earnings.

Positives

Low P/S ratio

Watchpoints

Extreme Forward P/E (183.50)
Negative P/B ratio

Future

25/100

Growth metrics are trending downward on an annual basis.

Positives

Recent Q/Q EPS growth

Watchpoints

Negative YoY Revenue growth
Severe YoY Earnings contraction

Past

30/100

Long-term price performance is heavily bearish.

Positives

Consistent earnings surprises

Watchpoints

5-year price decline of 52.6%
1-year price decline of 34.1%

Health

10/100

Deterministic health scores indicate a high risk of financial instability.

Positives

No standout positives identified.

Watchpoints

Piotroski F-Score 2/9
Current Ratio < 1.0

Dividend

5/100

Dividend is a 'value trap' and likely to be cut or suspended.

Positives

High nominal yield (16.35%)

Watchpoints

Absurd payout ratio (3962.91%)

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$3.67

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for CCEL and closest competitors.

Updated 2026-04-24

Company	5Y	3Y	1Y	6M	1M	1W
CCEL Cryo-Cell International, Inc. Primary	-52.6%	-3.2%	-34.1%	-15.6%	+23.6%	+6.7%
BTAI BioXcel Therapeutics, Inc. Peer	-99.8%	-99.6%	-30.1%	-56.4%	-37.0%	-18.7%
KYNB Kyntra Bio, Inc. Peer	-98.6%	-98.5%	+10.3%	-32.0%	+0.7%	+2.3%
NEPH Nephros, Inc. Peer	-63.0%	+102.8%	+42.6%	-46.5%	-1.4%	+3.6%
TELA TELA Bio, Inc. Peer	-95.4%	-93.3%	-29.1%	-57.4%	-18.9%	+12.7%

CCE

Cryo-Cell International, Inc.

Primary

-52.6%

-3.2%

-34.1%

-15.6%

+23.6%

+6.7%

BTA

BioXcel Therapeutics, Inc.

Peer

-99.8%

-99.6%

-30.1%

-56.4%

-37.0%

-18.7%

KYN

Kyntra Bio, Inc.

Peer

-98.6%

-98.5%

+10.3%

-32.0%

+0.7%

+2.3%

NEP

Nephros, Inc.

Peer

-63.0%

+102.8%

+42.6%

-46.5%

-1.4%

+3.6%

TEL

TELA Bio, Inc.

Peer

-95.4%

-93.3%

-29.1%

-57.4%

-18.9%

+12.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

183.5

1.34

-1.61

0.95

1.2

31.86

$29.56M

Profitability

Profit margins and return metrics

Profit Margin -8.52%

Operating Margin 9.96%

Gross Margin 63.53%

ROE N/A

ROA 0.19%

Growth

Revenue and earnings growth rates

Revenue Growth -3.6%

Earnings Growth -80.5%

Q/Q Revenue Growth -4.25%

Q/Q Earnings Growth -83.3%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

N/A

Current Ratio

0.62

Weak

Quick Ratio

0.55

Poor

Cash/Share

$0.36

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q1 2026

Revenue

$0.0B

Gross Margin

78.4%

Op. Margin

10.0%

Net Margin

0.6%

Total Assets

$0.1B

Liabilities

$0.1B

Equity

$-0.0B

Debt/Equity

-4.31x

Operating CF

$0.0B

CapEx

$-0.0B

Free Cash Flow

$0.0B

FCF Yield

90%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-14

$0.02

+195.0% surprise

2026-02-27

$-0.47

-417.3% surprise

2025-10-15

$0.1

+419.0% surprise

2025-07-15

$0.05

+217.0% surprise

Healthcare Sector Comparison

Comparing CCEL against 536 companies in the Healthcare sector (28 bullish, 158 neutral, 350 bearish)

Profit Margin

-8.52%

This Stock

-16.51%

Sector Avg

-48.4% (Weaker)

Revenue Growth

-3.6%

This Stock

129.68%

Sector Avg

-102.8% (Slower)

Current Ratio

0.62

This Stock

4.57

Sector Avg

-86.4% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
CCEL Cryo-Cell International, Inc.	BEARISH	$29.56M	-	-%	-8.5%	$3.67
BTAI BioXcel Therapeutics, Inc.	BEARISH	$29.51M	-	-%	-%	$1.09	Compare
KYNB Kyntra Bio, Inc.	BEARISH	$29.02M	-	-%	2848.6%	$7.17	Compare
NEPH Nephros, Inc.	BEARISH	$30.66M	26.18	12.7%	6.4%	$2.88	Compare
TELA TELA Bio, Inc.	BEARISH	$28.23M	-	-223.4%	-48.4%	$0.63	Compare

CCEL Cryo-Cell...

BEARISH

Mkt Cap

$30M

P/E

ROE

Price

$3.67

Compare with CCEL

KYNB Kyntra Bio, Inc.

Compare with CCEL

Compare with CCEL

Compare with CCEL

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2025-11-21	PORTNOY DAVID I	Chief Executive Officer	Stock Award	2,445	$9,937
2025-11-19	PORTNOY DAVID I	Chief Executive Officer	Stock Award	3,990	$16,171
2025-11-12	PORTNOY DAVID I	Chief Executive Officer	Stock Award	5,540	$22,911
2025-11-04	PORTNOY DAVID I	Chief Executive Officer	Stock Award	9,666	$42,764

PORTNOY DAVID I

Chief Executive Officer

Stock Award

2025-11-21

2,445 shares · $9,937

PORTNOY DAVID I

Chief Executive Officer

Stock Award

2025-11-19

3,990 shares · $16,171

PORTNOY DAVID I

Chief Executive Officer

Stock Award

2025-11-12

5,540 shares · $22,911

PORTNOY DAVID I

Chief Executive Officer

Stock Award

2025-11-04

9,666 shares · $42,764

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

10-Q

2026-04-14

CCEL filed its 10-Q on April 14, 2026. While specific financial highlights were not provided in the excerpt, the filing includes a dedicated section for Risk Factors under Item 1A.

8-K

2026-03-12

10-K

2026-02-27

CCEL filed its annual 10-K report on February 27, 2026. Due to the lack of detailed content in the provided excerpts, specific financial highlights and risk factors are unavailable.

8-K

2025-11-12

8-K

2025-10-23

CCEL filed an 8-K on October 23, 2025, likely to announce its third-quarter financial results.

10-Q

2025-10-15

CCEL filed its quarterly 10-Q report on October 15, 2025. The provided excerpt identifies the existence of a Risk Factors section, although specific financial highlights and detailed risk disclosures were not included in the available text.

DEF 14A

2025-09-26

CCEL filed a definitive proxy statement on September 26, 2025, providing shareholders with necessary information to vote on matters at the company's upcoming meeting.

8-K

2025-09-10

10-Q

2025-07-15

CCEL filed its quarterly 10-Q report on July 15, 2025. While the filing includes a section dedicated to Risk Factors, no specific financial highlights or detailed risk descriptions were provided in the available excerpts.

8-K

2025-05-22

8-K

2025-05-08

10-Q

2025-04-14

10-K

2025-02-28

8-K

2024-10-31

8-K

2024-10-30

Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning CCEL from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

CCEL

CCEL Cryo-Cell International, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Past News Coverage

Wait — Don't Miss Out!